Related references
Note: Only part of the references are listed.Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial
Joan Carles Trullas et al.
EUROPEAN HEART JOURNAL (2023)
Empagliflozin in Patients with Chronic Kidney Disease
William G. Herrington et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Adriaan A. Voors et al.
NATURE MEDICINE (2022)
Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)
P. Christian Schulze et al.
CIRCULATION (2022)
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
S. D. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload
Wilfried Mullens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the
Zachary L. Cox et al.
AMERICAN HEART JOURNAL (2021)
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial
Milton Packer et al.
CIRCULATION (2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C. Petrie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effects of Serelaxin in Patients with Acute Heart Failure
Marco Metra et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure
M. Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials
Yuliya Lytvyn et al.
CIRCULATION (2017)
Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure
Maria Rosa Costanzo et al.
JACC-HEART FAILURE (2016)
Clinical Effectiveness of Tolvaptan in Patients with Acute Decompensated Heart Failure and Renal Failure: Design and Rationale of the AQUAMARINE Study
Yuya Matsue et al.
CARDIOVASCULAR DRUGS AND THERAPY (2014)
Myocardial Recovery and the Failing Heart Myth, Magic, or Molecular Target?
Douglas L. Mann et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effect of Nesiritide in Patients with Acute Decompensated Heart Failure
C. M. O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effects of oral tolvaptan in patients hospitalized for worsening heart failure - The EVEREST outcome trial
Marvin A. Konstam et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure
Maria Rosa Costanzo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)